Preclinical studies show promise (C5aR1 blockade suppressing Th17 cells, CD46 agonism boosting antitumor immunity), but clinical translation faces challenges: (1) infection risks, (2) cytokine toxicity from overactivated T cells, and (3) immunosuppression in chronic diseases. Here, CD46 is linked to infection.